Skip to main content
SpringerLink
Log in
Book cover

Hemostasis in Dentistry pp 99–108Cite as

Review of Anticoagulants

  • Chapter
  • First Online:

  • 938 Accesses

Abstract

Anticoagulation therapy is utilized for many thromboembolic indications with oral therapy being the first-line therapy choice for long-term management of many of these disorders. Warfarin has been utilized for decades as the primary oral anticoagulant, and more recently, oral direct thrombin inhibitors and factor Xa inhibitors have emerged as alternative therapies. Subcutaneous and intravenous therapies are also often utilized in clinical practice most commonly as short-term therapies for bridging or the ability to initiate long-term anticoagulation. Dentists should be familiar with these agents and also be aware of potential drug interactions that may increase or decrease anticoagulant serum concentrations and alter clinical efficacy. Concomitant use with antiplatelet agents and the perioperative management of these agents, including the need for anticoagulation reversal, are discussed in other chapters of this book.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Cove CL, Hylek EM. An updated review of target specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndrome. J Am Heart Assoc. 2013;2:e000136. https://doi.org/10.1161/JAHA.113.000136.

    Article  PubMed  PubMed Central  Google Scholar 

  2. DeWilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart. 2006;92:1064–70. https://doi.org/10.1136/hrt.2005.069492.

    Article  PubMed  Google Scholar 

  3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70. https://doi.org/10.1001/jama.285.22.2864.

    Article  PubMed  Google Scholar 

  4. Hirsh J, Guyatt G, Albers GW, Harrington R, Schunemann HJ. Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence based clinical practice guidelines. Chest. 2008;133:110S–2S. https://doi.org/10.1378/chest.08-0652.

    Article  PubMed  Google Scholar 

  5. Alikhan R, Peters F, Wilmott R, Cohen AT. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol. 2004;57:1254–7. https://doi.org/10.1136/jcp.2003.013581.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Schaefer JK, McBane RD, Wysokinski WE. How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. Ann Hematol. 2016;95:437–49. https://doi.org/10.1007/s00277-015-2566-x.

    Article  PubMed  Google Scholar 

  7. Geerts WH, Bergqist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6):381S–453S. https://doi.org/10.1378/chest.08-0656.

    Article  PubMed  Google Scholar 

  8. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease. Antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based practice guidelines. Chest. 2012;141(2 Suppl):e419–94S. https://doi.org/10.1378/chest.11-2301.

    Article  Google Scholar 

  9. Ansell JE. Oral anticoagulant therapy-50 years later. Arch Intern Med. 1993;153:586–96. https://doi.org/10.1001/archinte.1993.00410050024005.

    Article  PubMed  Google Scholar 

  10. Bristol-Myers Squibb. Coumadin (warfarin) prescribing information. 2016. http://packageinserts.bms.com/pi/pi_coumadin.pdf. Accessed 23 Dec 2016.

  11. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119:8S–21S. https://doi.org/10.1378/chest.119.1_suppl.8S.

    Article  PubMed  Google Scholar 

  12. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: chest guideline and expert panel report. Chest. 2016;149(2):315–52. https://doi.org/10.1016/j.chest.2015.11.026.

    Article  PubMed  Google Scholar 

  13. Witt DM, Clark NP. Venous thromboembolism. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 9th ed. New York, NY: McGraw-Hill; 2014. p. 245–78.

    Google Scholar 

  14. Holbrook AM, Pereira JA, Labris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–106. https://doi.org/10.1001/archinte.165.10.1095.

    Article  PubMed  Google Scholar 

  15. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. https://doi.org/10.1056/NEJMoa0905561.

    Article  PubMed  Google Scholar 

  16. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709–18. https://doi.org/10.1056/NEJMoa1113697.

    Article  PubMed  Google Scholar 

  17. Boehringer-Ingelheim. Pradaxa (dabigatran) prescribing information. 2017. http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed 18 Jan 2017.

  18. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011;49(5):761–72. https://doi.org/10.1515/CCLM.2011.134.

    Article  PubMed  Google Scholar 

  19. Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and clinical monitoring of director acting oral anticoagulants: what clinicians need to know. Pharmacotherapy. 2017;37(2):236–48.

    Article  Google Scholar 

  20. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–14. https://doi.org/10.1056/NEJMoa1300615.

    Article  PubMed  Google Scholar 

  21. Liesenfel KH, Staab A, Hartter S, Fromella S, Clemens A, Lehr T. Pharmacometric characterization of dabigatran hemodialysis. Clin Pharmacokinet. 2013;52:453–62. https://doi.org/10.1007/s40262-013-0049-6.

    Article  Google Scholar 

  22. Janssen Pharmaceuticals. Xarelto (rivaroxaban) prescribing information. 2017. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s001lbl.pdf. Accessed 18 Jan 2017.

  23. Investigators EINSTEIN, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510. https://doi.org/10.1056/NEJMoa1007903.

    Article  Google Scholar 

  24. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. https://doi.org/10.1056/NEJMoa1009638.

    Article  PubMed  Google Scholar 

  25. Bristol-Myers Squibb Company and Pfizer Inc. Eliquis (apixaban) prescribing information. 2017. http://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed 18 Jan 2017.

  26. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. https://doi.org/10.1056/NEJMoa1107039.

    Article  PubMed  Google Scholar 

  27. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708. https://doi.org/10.1056/NEJMoa1207541.

    Article  PubMed  Google Scholar 

  28. Daiichi Sankyo. Savaysa (edoxaban) prescribing information. 2017. http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true. Accessed 19 Jan 2017.

  29. Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406. https://doi.org/10.1056/NEJMoa1306638.

    Article  PubMed  Google Scholar 

  30. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104. https://doi.org/10.1056/NEJMoa1310907.

    Article  PubMed  Google Scholar 

  31. Baglin T, Barrowcliffe TW, Cohen A, Greaves M. Guidelines for the use and monitoring of heparin. Br J Haematol. 2006;133(1):19–34. https://doi.org/10.1111/j.1365-2141.2005.05953.x.

    Article  PubMed  Google Scholar 

  32. GlaxoSmithKline. Arixtra (fondaparinux) prescribing information. 2017. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021345s023lbl.pdf. Accessed 19 Jan 2017.

  33. Spinler SA, Wittowsky AK, Nutescu E, Smythe MA. Anticoagulation monitoring part 2: unfractionated heparin and low-molecular-weight-heparin. Ann Pharmacother. 2005;39:1275–85. https://doi.org/10.1345/aph.1E524.

    Article  PubMed  Google Scholar 

  34. Greinacher A. Heparin-induced thrombocytopenia. N Engl J Med. 2015;373:252–61. https://doi.org/10.1056/NEJMoa1411910.

    Article  PubMed  Google Scholar 

  35. Nisio MD, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028–40. https://doi.org/10.1056/NEJMoa044440.

    Article  PubMed  Google Scholar 

  36. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838–43. https://doi.org/10.1161/01.CIR.103.14.1838.

    Article  PubMed  Google Scholar 

  37. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849–56. https://doi.org/10.1001/archinte.163.15.1849.

    Article  PubMed  Google Scholar 

  38. Hafner G, Roser M, Nauck M. Methods for the monitoring of direct thrombin inhibitors. Semin Thromb Hemost. 2002;28(5):425–30. https://doi.org/10.1055/s-2002-35282.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vizient Pharmacy Member Services, Vizient, Inc., Irving, TX, USA

    David P. Reardon

  2. Yale New Haven Hospital, New Haven, CT, USA

    Christopher Zemaitis

Authors
  1. David P. Reardon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher Zemaitis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David P. Reardon .

Editor information

Editors and Affiliations

  1. Department of Dentistry, St. Joseph’s Regional Medical Center, Department of Dentistry, Paterson, New Jersey, USA

    Richard P. Szumita

  2. Department of Pharmacy Services, Brigham and Women’s Hospital, Department of Pharmacy Services, Boston, Massachusetts, USA

    Paul M. Szumita

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Reardon, D.P., Zemaitis, C. (2018). Review of Anticoagulants. In: Szumita, R., Szumita, P. (eds) Hemostasis in Dentistry. Springer, Cham. https://doi.org/10.1007/978-3-319-71240-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-71240-6_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-71239-0

  • Online ISBN: 978-3-319-71240-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation